

VITEK® REVEAL™

GRAM NEGATIVE BC PANEL (GN02-AST)



- ✓ Antimicrobial susceptibility test (AST) results as early as 3 hours directly from positive blood culture.¹
- ✓ Wide antimicrobial coverage for gram-negative bloodstream infections, with 12 organisms and 16 drugs.

ANTIMICROBIAL DRUG	MIC CALLING RANGE (µg/ml)	A. baumannii-calcoaceticus complex	C. freundii complex	C. koseri	E. cloacae complex	E. coli	K. aerogenes	K. oxytoca	K. pneumoniae group	P. mirabilis	P. vulgaris	P. aeruginosa	S. marcescens
Amoxicillin / Clavulanate	4/2 - 16/8					✓		✓	✓	✓			
Ampicillin / Sulbactam	2/1 - 64/32					✓		✓	✓				
Cefepime	0.5 - 32		✓	✓	✓	✓	✓	✓	✓		✓		
Ceftazidime	0.12 - 32	✓	✓	✓	✓	✓	✓	✓	✓				
Ceftazidime / Avibactam	0.06/4 - 16/4		✓	✓	✓	✓		✓	✓		✓		
Ceftolozane / Tazobactam	0.12/4 - 32/4			✓	✓	✓	✓		✓	✓	✓		
Ceftriaxone	0.25 - 16				✓	✓	✓	✓	✓				
Ciprofloxacin	0.25 - 2		✓		✓	✓	✓	✓	✓		✓	✓	✓
Ertapenem	0.12 - 1				✓			✓	✓	✓			
Imipenem	0.5 - 8	✓		✓	✓	✓		✓	✓		✓	✓	✓
Levofloxacin	0.12 - 4		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Meropenem	0.5 - 16	✓			✓	✓		✓	✓	✓	✓	✓	✓
Meropenem / Vaborbactam	1/8 - 16/8		✓	✓	✓	✓	✓	✓	✓				
Piperacillin / Tazobactam	2/4 - 64/4			✓		✓		✓		✓			
Tobramycin	0.5 - 8		✓	✓	✓	✓	✓	✓	✓		✓	✓	✓
Trimethoprim / Sulfamethoxazole	2/38 - 4/76					✓	✓		✓				



System reports results with S/I/R interpretation according to FDA Susceptibility Test Interpretive Criteria (STIC)

NOVEL TECHNOLOGY DETERMINES MIC* DIRECTLY FROM POSITIVE BLOOD CULTURE

**OPTIMIZE DIAGNOSTICS.
OPTIMIZE THERAPY.**
With our **complete solution**
for **antimicrobial stewardship.**

The panel includes highly sensitive nanoporous sensors. The sensors change color in response to metabolic volatiles produced by microorganisms during growth to quantify antibiotic efficacy.

*minimum inhibitory concentration



SIMPLE PREP IN <3 MINUTES



Dilute



Decant



Inoculate



Cover with
Sensor Panel



Seal Assay



Run AST Panel

AVERAGE 5.5-6 HOURS TIME TO RESULT^{1,2}

Panel Information

Breakpoint Standards: CLSI / FDA STIC

VITEK REVEAL BC GN02-AST PANEL: 424883

References

- BMX.1129899 Clinical Trial Summary Report (proprietary, on file at bioMérieux).
- Rottman M et al. Clinical evaluation of the VITEK® REVEAL™ (previously branded SPECIFIC REVEAL) Rapid AST System with Gram-negative bacteremia samples in 6 hospitals in France and England. Poster presented at: ECCMID; 2022 May; Lisbon, Portugal.



bioMérieux, Inc. • 515 S Colorow Drive • Salt Lake City, UT 84108 • USA • Tel: (800) 682 2666 • Fax: (800) 968 9494
www.biomérieux-usa.com • @bioMérieuxUSA